Changes in the intestinal microbiota as a risk factor for dyslipidemia, atherosclerosis and the role of probiotics in their prevention
- 作者: Oynotkinova O.1,2,3, Nikonov E.2, Demidova T.2, Baranov A.2,3, Kryukov E.4, Dedov E.2, Karavashkina E.5
-
隶属关系:
- Research Institute of the Organization of Health Care and Medical Management
- Pirogov Russian National Research Medical University
- Lomonosov Moscow State University
- Burdenko Main Military Clinical Hospital
- Polyclinic No1
- 期: 卷 92, 编号 9 (2020)
- 页面: 94-101
- 栏目: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/46862
- DOI: https://doi.org/10.26442/00403660.2020.09.000784
- ID: 46862
如何引用文章
全文:
详细
The review presents an analysis of studies on the role of the intestinal microbiota and microbiome in lipid metabolism and the development of dyslipidemia, atherosclerosis and cardiovascular diseases. The role of the intestine as a metabolic organ with a multifactorial strain evolution, involved in lipid metabolism, cholesterol homeostasis and enterohepatic circulation is shown. The influence of microbial imbalance on the development of dyslipidemia and atherosclerosis is considered. Special attention is paid to preventive therapy with hypolipidemic probiotics. It is shown that the use of probiotics with hypolipidemic properties and consisting of a mixture of such strains as Lactobacillus plantarum CECT7527, CET7528 and CECT7529, mixtures of Lactobacillus acidophilus La-5, Bifidobacterium lactis BB-12, Bifidobacterium animalis lactis BB-12 contribute to reducing the level of LDL-C, CCS, TG, are safe and well tolerated, can be used as an adjuvant non-drug therapy in combination with hypolipidemic drugs for dyslipidemia, multifocal atherosclerosis.
作者简介
O. Oynotkinova
Research Institute of the Organization of Health Care and Medical Management; Pirogov Russian National Research Medical University; Lomonosov Moscow State University
编辑信件的主要联系方式.
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0002-9856-8643
д.м.н., проф., нач. отд. ГБУ НИИОЗММ, проф. каф. пропедевтики внутренних болезней и лучевой диагностики ФГБОУ ВО «РНИМУ им. Н.И. Пирогова», проф. каф. фак-та фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова»
俄罗斯联邦, MoscowE. Nikonov
Pirogov Russian National Research Medical University
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0002-8396-1936
д.м.н., проф., зав. каф. гастроэнтерологии ФГБОУ ВО «РНИМУ им. Н.И. Пирогова»
俄罗斯联邦, MoscowT. Demidova
Pirogov Russian National Research Medical University
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0001-6385-540X
д.м.н., проф., зав. каф. эндокринологии ФГБОУ ВО «РНИМУ им. Н.И. Пирогова»
俄罗斯联邦, MoscowA. Baranov
Pirogov Russian National Research Medical University; Lomonosov Moscow State University
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0002-3981-0073
д.м.н., проф., ФГБОУ ВО «РНИМУ им. Н.И. Пирогова», зав. каф. терапии фак-та фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова»
俄罗斯联邦, MoscowE. Kryukov
Burdenko Main Military Clinical Hospital
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0002-8396-1936
чл.-кор. РАН, д.м.н., проф., нач. ФГБУ «ГВКГ им. Н.Н. Бурденко»
俄罗斯联邦, MoscowE. Dedov
Pirogov Russian National Research Medical University
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0002-9118-3708
д.м.н., проф. каф. госпитальной терапии ФГБОУ ВО «РНИМУ им. Н.И. Пирогова»
俄罗斯联邦, MoscowE. Karavashkina
Polyclinic No1
Email: olga-oynotkinova@yandex.ru
ORCID iD: 0000-0002-7090-5003
врач-терапевт ФГБУ «Поликлиника №1»
俄罗斯联邦, Moscow参考
- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 Update: a report from the american heart association. Circulation. 2016;133:e38-e360. doi: 10.1161/cir.0000000000000350
- Стратегические приоритеты Программы ВОЗ по сердечно-сосудистым заболеваниям. Обзор доклада ВОЗ, 2005 г. [Strategic priorities for the WHO Cardiovascular Disease Program. Revier of the 2005 WHO (In Russ.)].
- The L. GBD 2017: A fragile world. Lancet (Lond. Engl.). 2018;392:1683. doi: 10.1016/S0140-6736(18)32858-7
- Organization WH. Cardiovascular Disease. Availabe online: https://www.who.int/cardiovascular_diseases/about_cvd/en/ (accessed on 13 November 2019).
- Francisco Abadia-Molina, et al. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related. Cardiovasc Dis Nut. 2020;12(3):605. doi: 0.3390/nu12030605
- Lau K, Srivatsav V, Rizwan A, et al. Bridging the gap between gut microbial dysbiosis and cardiovascular diseases. Nutrients. 2017;9:E859. doi: 10.3390/nu9080859
- Wang Z, Klipfell E, Bennett BJ, et al. Intestinal flora Phosphatidylcholine metabolism contributes to cardiovascular disease. Nature. 2011;472:57-63. doi: 10.1038/nature09922
- Drosos I, Tavridou A, Kolios G. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. Metabolism. 2015;64:476-81. doi: 10.1016/j.metabol.2015.01.007
- Gregory JC, BuffaJA, OrgE, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015;290:5647-60. doi: 10.1074/jbc.M114.618249
- Jie Z, Xia H, Zhong SL, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. doi: 10.1038/s41467-017-00900-1
- Kasahara K, Tanoue, T, Yamashita T, et al. Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. J Lipid Res. 2017;58:519-28. doi: 10.1194/jlr.M072165
- Koopen AM, Groen AK, et al. Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk. Curr Opin Lipidol. 2016;27:615-22. doi: 10.1097/mol.0000000000000357
- Anbazhagan AN, Priyamvada S, Priyadarshini M. Gut microbiota in vascular disease: therapeutic target? Curr Vasc Pharmacol. 2017;15:291-5. doi: 10.2174/15701611156661701050 95834
- Santisteban MM, Qi Y, Zubcevic J, et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2017;120:312-23. doi: 10.1161/circresaha.116.309006
- Roy S, Trinchieri G. Microbiota: A key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17:271-85. doi: 10.1038/nrc.2017.13
- Miele L, Giorgio V, Alberelli MA, et al. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep. 2015;17:120. doi: 10.1007/s11886-0150671-z
- Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-85. doi: 10.1038/nm.3145
- Kamo T, Akazawa H, Suda W, et al. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One. 2017;12:e0174099. doi: 10.1371/journal.pone.0174099
- Tang WH, KitaiT, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120:1183-96. doi: 10.1161/circresaha.117.309715
- Backhed F, Ley RE, Sonnenburg JL. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-20. doi: 10.1126/science.1104816
- D’ Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. Clin Chim Acta. 2015;451(Pt A):97-102. doi: 10.1016/j.cca.2015.01.003
- Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337-40. doi: 10.1016/j.cell.2016.01.013
- Fuller M. Determination of protein and amino acid digestibility in foods including implications of gut microbial amino acid synthesis. Br J Nutr. 2012;108:238-46. doi: 10.1017/S0007114512002279
- Cani PD, Delzenne NM. Involvement of the gut microbiota in the development of low grade in ammation associated with obesity: focus on this neglected partner. Acta Gastroenterol Belg. 2010;73:267-9. doi: 10.4161/gmic.19625
- Carvalho BM, Guadagnini D, Tsukumo DM, et al. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia. 2012;55:2823-34. doi: 10.1007/s00125-012-2648-4
- Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136:65-80. doi: 10.1053/j.gastro.2008.10.080
- Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65. doi: 10.1038/nature08821
- Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13;486(7402):207-14. doi: 10.1038/nature11234
- Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
- Peterson DA, Frank DN, Pace NR, et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008 Jun 12;3(6):417-27. doi: 10.1016/j.chom.2008.05.001
- Carneiro de Mur M. Nonalcoholic steatohepatitis. Clin Perspectiv Gastroenterol Hepatol. 2001;2:12-5.
- Emoto T, Yamashita T, Kobayashi T, et al. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction y length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease. Heart Vessels. 2017;32:39-46. doi: 10.1007/s00380-016-0841-y
- Ойноткинова О.Ш., Никонов Е.Л., Гиоева И.З. Роль микробиоты кишечника в патогенезе дислипидемии и ассоциированных метаболических нарушений. Доказательная гастроэнтерология. 2017;6(2):29-34 [Oynotkinova OSh, Nikonov EL, GioivaI Z. The role of the gut microbiota in the pathogenesis of dyslipidemia and associated metabolic disorders. Evidence-Based Gastroenterology. 2017;6(2):29-34 (In Russ.)]. doi: 10.17116/dokgastro20176229-34
- MacFarlane MR, Liang G, Engelking LJ, et al. Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine. J Biol Chem. 2014 Jan 24;289(4):2148-56. doi: 10.1074/jbc.M113.524041
- Brown JM, Hazen SL. Microbial modulation of cardiovascular diseases. Native Rev Microbiol. 2018;16:171-81. doi: 10.1038/nrmicro.2017.149
- Bergeron N, Williams PT, Lamendella R, et al. Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a metabolite of the intestinal microbiome associated with the risk of CVD. Br J Nutr. 2016;116:2020-9. doi: 10.1017/s0007114516004165
- Li X, Shimizu Y, Kimura I. Gut microbial metabolite short-chain fatty acids and obesity. Biosci Microbiota Food Health. 2017;36(4):135-40. doi: 10.12938/bmfh.17-010. PMID: 29038768.
- Battson ML, Lee DM, Weir TL, et al. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 2018;56:1-15. doi: 10.1016 / j.jnutbio.2017.12.010
- Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: Prospective results from a large population study. Circulation. 2001;103:1064-70. doi: 10.1161/01.cir.103.8.1064
- Harris K, Kassis A, Major G. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes. 2012:879151. doi: 10.1155/2012/879151
- Neves AL, Coelho J, Couto L, et al. Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol. 2013;51:R51-R64. doi: 10.1530/JME-13-0079
- Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74. doi: 10.1038/nature01323
- Chacon MR, Lozano-Bartolome J, Portero-Otin M, et al. The gut mycobiome composition is linked to carotid atherosclerosis. Benef Microbes. 2017;9:1-14. doi: 10.3920/bm2017.002944
- Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511. doi: 10.1038/nri1391
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801. doi: 10.1016/j.cell.2006.02.015
- Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9:535-42. doi: 10.1038/nri2587
- Guzzo C, Ayer A, Basta S, et al. IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J Immunol. 2012;188:864-73. doi: 10.4049/jimmunol.1101912
- Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10:416-21. doi: 10.1038/nm1008
- Laman JD, Schoneveld AH, Moll FL, et al. Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol. 2002;90:119-23. doi: 10.1016/S0002-9149(02)02432-3
- Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gumetagenome. Nat Commun. 2012;3:1245. doi: 10.1038/ncomms2266
- Philpott DJ, Sorbara MT, Robertson SJ, et al. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol. 2014;14:9-23. doi: 10.1038/nri3565
- Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-4. doi: 10.1126/science.1104911
- Kanno S, Nishio H, Tanaka T, et al. Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/-mice. J Immunol. 2015;194:773-80. doi: 10.4049/jimmunol.1302841
- Kamo T, Akazawa H, Suda W, et al. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One. 2017;12(3):e0174099. doi: 10.1371/journal.pone.0174099
- Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183-96. doi: 10.1161/CIRCRESAHA. 117.309715
- Lever M, George PM, Slow S, et al. Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: An observational study. PLoS ONE. 2014;9:e114969. doi: 10.1371/journal.pone.011496
- Mafune A, Iwamoto T, Tsutsumi Y, et al. Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin Exper Nephrol. 2016;20(5):731-9. doi: 10.1007/s10157-015-1207-у
- Senthong V, Wang Z, Li XS, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc. 2016;5(6):e002816. doi: 10.1161/JAHA.115.002816
- Yu D, Shu XO, Rivera ES, et al. Urinary levels of trimethylamine-N-Oxide and incident coronary heart disease: a prospective investigation among urban Chinese adults. J Am Heart Assoc. 2019;8(1):e010606. doi: 10.1161/JAHA.118.010606
- Gimbrone MA, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circul Res. 2016;118(4):620-36. doi: 10.1161/CIRCRESAHA.115.306301
- Liu Z, Li J, Liu H, et al. The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease. Atherosclerosis. 2019;284:121-8. doi: 10.1016/j.atherosclerosis. 2018.11.038
- Karlsson FH, Fåk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3(1):1245. doi: 10.1038/ncomms2266
- Liu H, Yang C, Jing Y, et al. Ability of lactic acid bacteria isolated from mink to remove cholesterol: in vitro and in vivo studies. Can J Microbiol. 2013;59(8):563-9. doi: 10.1139/cjm-2013-0200
- Li J, Lin S, Vanhoutte PM. Akkermansia muciniphilaprotects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE-/- mice. Circulation. 2016;133(24):2434-46. doi: 10.1161/ CIRCULATIONAHA.115.019645
- Midtvedt T. Microbial bile acid transformation. Am J Clin Nutr. 1974;27:1341-7. doi: 10.1093/ajcn/27.11.1341
- Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physio Rev. 2009;89:147-91. doi: 10.1152/physrev.00010.2008
- Ridlon JM, Harris SC, Bhowmik S, et al. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7:22-39. doi: 10.1080/19490976.2015.1127483
- Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Ann Rev Pathol. 2006;1:297-329. doi: 10.1146/annurev.pathol.1.110304.100100
- Wahlstrom A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41-50. doi: 10.1016/j.cmet.2016.05.005
- Li T, Chiang JY. Bile acids as metabolic regulators. Curr Opin Gastroenterol. 2015;31:159-65. doi: 10.1097/mog.0000000000000156
- Szeto FL, Reardon CA, Yoon D, et al. Vitamin D receptor signaling inhibits atherosclerosis in mice. Mol Endocrinol. 2012;26:1091-101. doi: 10.1210/me.2011-1329
- Studer E, Zhou X, Zhao R, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012;55:267-76. doi: 10.1002/hep.24681
- Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381-91. doi: 10.3748/wjg.v20.i23.7381
- Fuentes MC, Lajo T, Carrión JM, Cuñé J. A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol. Med J Nutrition Metab. 2016;9(2):125-35. doi: 10.3233/MNM-160065
- Mukerji P, Roper JM, Stahl B, et al. Safety evaluation of AB-LIFE(®) (Lactobacillus plantarum CECT 7527, 7528 and 7529): Antibiotic resistance and 90-day repeated-dose study in rats. Food Chem Toxicol [Internet]. 2016 Jun;92:117-28. doi: 10.1016/j.fct.2016.03.018
- Roper JM, Stahl B, Smith AB, et al. Safety evaluation of AB-LIFE® (Lactobacillus plantarum CECT 7527, 7528 and 7529): Antibiotic resistance and 90-day repeated-dose study in rats. Food Chem Toxicol. 2016 Jun;92:117-28. doi: 10.1016/j.fct.2016.03.018
- Bosch M, Fuentes MC, Audivert S, et al. Lactobacillus plantarum CECT 7527, 7528 and 7529: Probiotic candidates to reduce cholesterol levels. J Sci Food Agric. 2014 Mar 15;94(4):803-9. doi: 10.1002/jsfa.6467
- Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012 Nov;66(11):1234-41. doi: 10.1038/ejcn
- Gilliland SE, Nelson CR, Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol. 1985;49:377-81.
- Liong MT, Shah NP. Acid and bile tolerance and cholesterol removal ability of lactobacilli strains. J Dairy Sci. 2005;88:55-66.
- Pereira DIA, Gibson GR. Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol. 2002 Sep;68(9):4689-93. doi: 10.1128/aem.68.9.4689-4693.2002
- Agerholm-Larsen L, Bell ML, Grunwald GK, Astrup A. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr. 2000. doi: 10.1038/ sj.ejcn.1601104
- Junli Ma, Houkai Li. The Role of Gut Microbiota in Atherosclerosis and Hypertension. Front Pharmacol. 2018;9:1082. doi: 10.3389/fphar.2018.01082